Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Zhendong Jiang, Youming Huang, Hui Jiang, Ping Wang, Lei Zhang, Li Ren & Ping Han. (2020) Albuterol combined with tiotropium bromide to improve the conditions and pulmonary functions of patients with acute exacerbation of chronic obstructive pulmonary disease. All Life 13:1, pages 668-674.
Read now
Read now
Christopher F. Bell, Anna D. Coutinho, Eileen Farrelly, Tasneem Lokhandwala & Pamela Landsman-Blumberg. (2018) Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care. Journal of Medical Economics 21:6, pages 629-638.
Read now
Read now
Donald P Tashkin & Charlie Strange. (2018) Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 2587-2601.
Read now
Read now
Cheng Wang, Jun-Xiong Li, Dang Tang, Jian-Qing Zhang, Li-Zhou Fang, Wei-Ping Fu, Ling Liu & Lu-Ming Dai. (2017) Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide–formoterol treatment. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3511-3521.
Read now
Read now
Michele R Wilson, Jeetvan G Patel, Amber Coleman, Cheryl L McDade, Richard H Stanford & Stephanie R Earnshaw. (2017) Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 997-1008.
Read now
Read now
Articles from other publishers (1)
Melissa H. Roberts, Douglas W. Mapel & Hans Petersen. (2019) Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease. Drugs - Real World Outcomes 7:1, pages 1-17.
Crossref
Crossref